Clinical Trials Logo

Migraine clinical trials

View clinical trials related to Migraine.

Filter by:

NCT ID: NCT02570633 Completed - Migraine Clinical Trials

Ginger Capsules for the Prophylactic Treatment of Migraine

Start date: April 2015
Phase: N/A
Study type: Interventional

The main objective of the study is to evaluate ginger efficacy as an prophylactic treatment of migraine.

NCT ID: NCT02568644 Completed - Migraine Clinical Trials

Ginger Capsules for the Acute Treatment of Migraine Attacks

Start date: July 2014
Phase: N/A
Study type: Interventional

The main objective of the study was to evaluate ginger efficacy as an adjuvant to ketoprofen for the treatment of headache and other symptoms related with migraine attacks.

NCT ID: NCT02542605 Completed - Migraine Clinical Trials

To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients

Start date: November 11, 2015
Phase: Phase 1
Study type: Interventional

Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.

NCT ID: NCT02518464 Completed - Migraine Clinical Trials

Ticagrelor Therapy for RefrACTORy Migraine Study

TRACTOR
Start date: October 2015
Phase: Phase 4
Study type: Interventional

This is a prospective, open-label, single-arm pilot study treating 40 subjects to assess the hypothesis that P2Y, G protein-coupled 12 (P2Y12) inhibition with Brilinta/ticagrelor (90 mg by mouth (PO) twice a day) reduces episodic and/or chronic migraine headache symptoms in patients with right to left shunt. Headache frequency while on Brilinta/ticagrelor will be compared with the documented baseline for each subject. If the Brilinta/ticagrelor therapy was effective (> 50% reduction in monthly headache days), the subject could elect to continue therapy for an additional two months (56 days), while continuing to complete daily headache logs.

NCT ID: NCT02486276 Completed - Migraine Clinical Trials

The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache

Start date: June 2015
Phase: N/A
Study type: Interventional

To develop a pragmatic migraine model the investigators will induce headache in healthy volunteers and in patients with migraine without aura with a phosphodiesterase inhibitor (cilostazol). If the headache responds to sumatriptan, the model can be used to test new drug candidates.

NCT ID: NCT02485340 Completed - Migraine Clinical Trials

The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache

Start date: April 2015
Phase: N/A
Study type: Interventional

To develop a pragmatic migraine model the investigators will induce headache in healthy volunteers and in patients with migraine without aura with a long lasting Nitrogen Oxide (NO) donor. If the headache responds to sumatriptan, the model can be used to test new drug candidates.

NCT ID: NCT02483585 Completed - Migraine Clinical Trials

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention

ARISE
Start date: July 20, 2015
Phase: Phase 3
Study type: Interventional

To evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days, in adults with episodic migraine.

NCT ID: NCT02472418 Completed - Migraine Clinical Trials

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

Start date: June 5, 2015
Phase: Phase 2
Study type: Interventional

Crossover study of DFN-15 dose A versus DFN-15 dose B versus Placebo in the treatment of migraine headaches.

NCT ID: NCT02468622 Completed - Migraine Clinical Trials

Transcriptomic and Biochemical Changes During a Migraine Attack

Start date: August 2015
Phase:
Study type: Observational

Despite the fact that migraine is a common disorder, the pathogenesis is still not fully elucidated. Studying transcriptomic and biochemical changes during induced and spontaneous migraine-attacks will enhance our understanding and may point to new targets for drug development.

NCT ID: NCT02456740 Completed - Migraine Clinical Trials

Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention

STRIVE
Start date: July 17, 2015
Phase: Phase 3
Study type: Interventional

The primary objective of the study was to evaluate the effect of erenumab compared to placebo on the change from baseline in monthly migraine days.